Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy.
Müller TR, Jarosch S, Hammel M, Leube J, Grassmann S, Bernard B, Effenberger M, Andrä I, Chaudhry MZ, Käuferle T, Malo A, Cicin-Sain L, Steinberger P, Feuchtinger T, Protzer U, Schumann K, Neuenhahn M, Schober K, Busch DH. Müller TR, et al. Among authors: feuchtinger t. Cell Rep Med. 2021 Aug 17;2(8):100374. doi: 10.1016/j.xcrm.2021.100374. eCollection 2021 Aug 17. Cell Rep Med. 2021. PMID: 34467251 Free PMC article.
Systematic identification of cancer-specific MHC-binding peptides with RAVEN.
Baldauf MC, Gerke JS, Kirschner A, Blaeschke F, Effenberger M, Schober K, Rubio RA, Kanaseki T, Kiran MM, Dallmayer M, Musa J, Akpolat N, Akatli AN, Rosman FC, Özen Ö, Sugita S, Hasegawa T, Sugimura H, Baumhoer D, Knott MML, Sannino G, Marchetto A, Li J, Busch DH, Feuchtinger T, Ohmura S, Orth MF, Thiel U, Kirchner T, Grünewald TGP. Baldauf MC, et al. Among authors: feuchtinger t. Oncoimmunology. 2018 Jul 23;7(9):e1481558. doi: 10.1080/2162402X.2018.1481558. eCollection 2018. Oncoimmunology. 2018. PMID: 30228952 Free PMC article.
Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections.
Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, Handgretinger R, Lang P, Busch DH, Feuchtinger T. Stief TA, et al. Among authors: feuchtinger t. Mol Ther. 2022 Jan 5;30(1):198-208. doi: 10.1016/j.ymthe.2021.05.021. Epub 2021 May 29. Mol Ther. 2022. PMID: 34058386 Free PMC article.
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins.
Blaeschke F, Stenger D, Apfelbeck A, Cadilha BL, Benmebarek MR, Mahdawi J, Ortner E, Lepenies M, Habjan N, Rataj F, Willier S, Kaeuferle T, Majzner RG, Busch DH, Kobold S, Feuchtinger T. Blaeschke F, et al. Among authors: feuchtinger t. Blood Cancer J. 2021 Jun 4;11(6):108. doi: 10.1038/s41408-021-00499-z. Blood Cancer J. 2021. PMID: 34088894 Free PMC article. No abstract available.
Modular pooled discovery of synthetic knockin sequences to program durable cell therapies.
Blaeschke F, Chen YY, Apathy R, Daniel B, Chen AY, Chen PA, Sandor K, Zhang W, Li Z, Mowery CT, Yamamoto TN, Nyberg WA, To A, Yu R, Bueno R, Kim MC, Schmidt R, Goodman DB, Feuchtinger T, Eyquem J, Jimmie Ye C, Carnevale J, Satpathy AT, Shifrut E, Roth TL, Marson A. Blaeschke F, et al. Among authors: feuchtinger t. Cell. 2023 Sep 14;186(19):4216-4234.e33. doi: 10.1016/j.cell.2023.08.013. Cell. 2023. PMID: 37714135 Free article.
Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia.
Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser AD, Assenmacher M, Döring M, Feucht J, Feuchtinger T. Blaeschke F, et al. Among authors: feuchtinger t. Cancer Immunol Immunother. 2018 Jul;67(7):1053-1066. doi: 10.1007/s00262-018-2155-7. Epub 2018 Mar 31. Cancer Immunol Immunother. 2018. PMID: 29605883 Free PMC article.
136 results